Product Code: RP-ID-10076418 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10076418
Market Overview:
Myocardial Ischemia Market Segmentation by Route of Administration (Injectable, and Oral); by End-User (Ambulatory Centers, Hospitals & Clinics, and Diagnostic Center); and by Type (Asymptomatic, and Symptomatic)-Global Demand Analysis & Opportunity Outlook 2031
Global Myocardial Ischemia Market Highlights Over 2022 - 2031
The global myocardial ischemia market is estimated to grow at a ~6% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of approximately USD 1,817.0 million in 2021. The growth of the market can be attributed to the high prevalence of diabetes, cardiovascular, and other diseases worldwide. In addition, there has been a surge in the mortality rate across the globe owing to these chronic diseases, which is also expected to drive the growth of the market in the coming years. According to the World Health Organization (WHO), cardiovascular diseases accounted for 32 percent of all global deaths in the year 2019. Furthermore, an increase in the government and different organizations supporting people suffering from myocardial ischemia is expected to drive the growth of the global myocardial ischemia market.
GET A SAMPLE COPY OF THIS REPORT
The global myocardial ischemia market is segmented by type into asymptomatic and symptomatic. Out of these, the asymptomatic segment is anticipated to hold the largest share over the forecast period in the market owing to the rise in the number of silent myocardial ischemia cases that lead to sudden deaths.
Global Myocardial Ischemia Market Regional Synopsis
Regionally, the global myocardial ischemia market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region is estimated to witness modest growth over the forecast period on the back of the high prevalence of patients dealing with cardiovascular diseases and diabetes. As per the Centers for Disease Control and Prevention, 11.3 percent of the U.S population is suffering from diabetes. Furthermore, advancement in research and development and healthcare infrastructure is further expected to surge the growth of the myocardial ischemia market in the North America region.
Market Segmentation
Our in-depth analysis of the global myocardial ischemia market includes the following segments:
By Route of Administration
-
Injectable
-
Oral
By End-User
-
Ambulatory Centers
-
Hospitals & Clinics
-
Diagnostic Center
By Type
-
Asymptomatic
-
Symptomatic
Growth Drivers and Challenges Impacting the Growth of the Global Myocardial Ischemia Market
Growth Drivers
-
High prevalence of diabetes, cardiovascular, and other diseases
-
Surge in the mortality rate across the globe due to chronic diseases
Challenges
-
High cost for the treatment of myocardial ischemia
-
Lack of professional medical employees for the treatment of disease
Key Companies Dominating the Global Myocardial Ischemia Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global myocardial ischemia market that are included in our report are Boston Scientific Corporation, PHARMA’S ALMANAC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GSK plc, Bayer AG, RENOVA, Novartis AG, Mylan (Viatris Inc.), Merck KGaA, and others.
Latest Developments in the Global Myocardial Ischemia Market:
-
25 June 2020: Piramal Pharma announced the acquisition of a solid oral dosage drug product facility in Sellersville through an agreement with G&W Laboratories Inc.
-
14 June 2022: Merck KGaA announced its collaboration with Agilent Technologies in order to advance Process Analytical Technologies.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Boston Scientific Corporation
- PHARMA’S ALMANAC
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GSK plc
- Bayer AG
- RENOVA
- Novartis AG
- Mylan (Viatris Inc.)
- Merck KGaA
Related Reports
Proof of Quality & Reliability
